Director dealing and Grant of Options

RNS Number : 6286S

Cambridge Cognition Holdings PLC

09 July 2015

 

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

Director dealing and Grant of Options

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests announces that on 9^th July 2015 (the "Date of Grant") Steven Powell, Chief Operating Officer, was awarded options over 125,000 ordinary shares of 1 pence each ("Ordinary Shares") in the Company (the "Options"), pursuant to the terms of a share option contract, at an exercise price of 82.5 pence per Ordinary Share, being the closing share price on 8^th July 2015. The Options are exercisable from the Date of Grant until 31 December 2017 subject to the following performance criteria:

-   62,500 Ordinary Shares will be exercisable when the Company's share price has equalled or exceeded 120 pence per Ordinary Share for two consecutive dealing days; and

-   62,500 Ordinary Shares will be exercisable when the Company's share price has equalled or exceeded 200 pence per Ordinary Share for two consecutive dealing days.

The Options are exercisable for 10 years from the Date of Grant and Steven Powell holds no other Options over Ordinary Shares.

In addition the Company has also granted 422,200 Options to various other employees and consultants on the same terms as above.

Enquiries:

Cambridge Cognition Holdings plc	www.cambridgecognition.com
Steven Powell, Chief Operating Officer	Tel: [phone]
Nick Walters, Chief Financial Officer
finnCap Ltd (Nomad and Broker)	Tel: [phone]
Geoff Nash/Simon Hicks		(Corporate Finance)
Malar Velaigam	(Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic  scientists  in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function.  In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing.  Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

 

END

 

 

MSCBBGDRRGGBGUC